Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.

ABSTRACT:

Background and aims

Patients with long atrial high-rate episodes (AHREs) ≥24 h and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared with no anticoagulation in these patients.

Methods

This secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High-rate episodes (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared with placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outc

SUBMITTER: Becher N 

PROVIDER: S-EPMC10919916 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature